▶ Manufacturer: Ilhwa Co., Ltd.
▶ Sold by: Ilhwa Co., Ltd.
▶ Insurance code : 640902330
▶ Storage : Airtight container, store at room temperature (1 to 30℃)
White oblong film-coated tablet
Glimepiride 2mg, Metformin hydrochloride 500mg
This drug is to be administered once or twice a day with meals or immediately before meals.
Dose may be adjusted depending on current therapy, effectiveness, and tolerance of individual patients, and appropriate blood glucose monitoring must be performed to this end. Normally, therapy may be begun at low doses, and adjusted with consideration for drugs currently taken by the patient and his/her blood glucose levels. In clinical trials, the initial daily dose was 2mg/500mg glimepiride and metformin hydrochloride, with administration of up to 8mg/2000mg glimepiride and metformin hydrochloride after gradual increases depending on blood glucose monitoring results. Glimepiride as a single drug has almost no additional benefits when administered at a dose of 4mg or higher, but some patients exhibited better metabolic regulation when dose was increased to 6mg (or 8mg). When using as a replacement therapy for concomitant therapy, administer based on the administration method and dose of the currently concomitantly administered glimepiride and metformin hydrochloride. Even if previous administration has been skipped, patients must not take more than the dose for a single administration at the next time of administration.
Together with dietary and exercise therapy in patients of non insulin-dependent diabetes (Type II)
- When blood glucose regulation effect of single therapy using glimepiride or metformin is insufficient
- Replacement for concomitant therapy of glimepiride and metformin
White oblong film-coated tablet
Glimepiride 2mg, Metformin hydrochloride 500mg
This drug is to be administered once or twice a day with meals or immediately before meals.
Dose may be adjusted depending on current therapy, effectiveness, and tolerance of individual patients, and appropriate blood glucose monitoring must be performed to this end. Normally, therapy may be begun at low doses, and adjusted with consideration for drugs currently taken by the patient and his/her blood glucose levels. In clinical trials, the initial daily dose was 2mg/500mg glimepiride and metformin hydrochloride, with administration of up to 8mg/2000mg glimepiride and metformin hydrochloride after gradual increases depending on blood glucose monitoring results. Glimepiride as a single drug has almost no additional benefits when administered at a dose of 4mg or higher, but some patients exhibited better metabolic regulation when dose was increased to 6mg (or 8mg). When using as a replacement therapy for concomitant therapy, administer based on the administration method and dose of the currently concomitantly administered glimepiride and metformin hydrochloride. Even if previous administration has been skipped, patients must not take more than the dose for a single administration at the next time of administration.
Together with dietary and exercise therapy in patients of non insulin-dependent diabetes (Type II)
- When blood glucose regulation effect of single therapy using glimepiride or metformin is insufficient
- Replacement for concomitant therapy of glimepiride and metformin
